Compare AKTX & TGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKTX | TGE |
|---|---|---|
| Founded | N/A | 2023 |
| Country | United States | France |
| Employees | N/A | 166 |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 12.6M |
| IPO Year | 2014 | N/A |
| Metric | AKTX | TGE |
|---|---|---|
| Price | $7.18 | $0.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $25.50 | N/A |
| AVG Volume (30 Days) | 32.2K | ★ 880.8K |
| Earning Date | 11-12-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.18 |
| 52 Week High | $29.32 | $1.69 |
| Indicator | AKTX | TGE |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 24.12 |
| Support Level | $5.01 | N/A |
| Resistance Level | $9.91 | $0.99 |
| Average True Range (ATR) | 0.90 | 0.08 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 24.25 | 8.06 |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.